Keenova Therapeutics and Par Health
Laboratory Analyst with 4–8 years of experience testing in‑process, hold time, finished product, commercial, validation, and market complaint samples in a pharmaceutical laboratory. The role focuses on supporting laboratory quality systems and ensuring compliance with regulatory practices such as cGLP and cGDP.
Keenova Therapeutics and Par Health are the successor entities formed after Mallinckrodt's merger with Endo; Keenova Therapeutics focuses on specialty therapeutics across rare and unaddressed conditions (immunology, urology, hepatology, ophthalmology, orthopedics, critical care), while Par Health develops high-quality generics, sterile injectables, and active pharmaceutical ingredients (APIs) with a robust U.S.-advantaged manufacturing network.
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
Aug 1, 2025
With merger in the books, Mallinckrodt and Endo rebrand as Keenova and spin off Par Health
Nov 11, 2025
Judge Says 'Error' Kept Mallinckrodt Execs In Investor Suit
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Keenova Therapeutics and Par Health.
Keenova Therapeutics and Par Health didn’t post a salary, so this is our estimate from similar listings.
Mallinckrodt Names Christiana Stamoulis President and CFO
Aug 6, 2025
Quality Control Biochem / Chemistry Testing L1-1
Sanofi
Team Member - Quality Control (HPLC)
drreddyslaboratorieslimited.com
Quality Control Chemist
Eagle Analytical
AS&T Specialist
Sandoz
Quality Control Analyst
WuXi AppTec
Team Member - Quality Control ( Analytical Method Validations/Transfers)
drreddyslaboratorieslimited.com